New recruits at OBN

Bill Fleming and David Browning join board of the not-for-profit membership organisation supporting UK's life sciences companies, corporate partners and investors

OBN, the organisation that brings together UK life science companies, has announced a promotion and a new appointment. Bill Fleming has been internally recruited from Non-Executive Director to Chairman of the Board replacing Sally Waterman, with David Browning filling the newly open Non-Executive Director position.

Fleming served as a Non-Executive Director from April 2017 and is member of OBN’s Investment and Tax Special Interest Group. John Harris, CEO of OBN said Fleming will use his “in-depth knowledge of OBN” to “take on a more active role in providing leadership.”

The outside recruit Browning is currently the CEO of Oxford Cancer Biomarkers who are members of OBN and has 37 years of experience in healthcare innovation.

Commenting on the appointment, Browning said he has “been an advocate of OBN for many years”.

Both John Harris and Sally Waterman say they look forward to seeing the results of the experience these two will bring to the board.

You may also like

Research & Development

ABPI and OBN sign Memorandum of Understanding

To look for partnership initiatives to help build better public profile and understanding of all biosciences
Ingredients

FrieslandCampina Ingredients debuts consumer-driven concepts at Vitafoods Europe

The company will exhibit its omega-3 ingredient, as well as its active gut health solution
Pharmaceutical

High-precision temperature control solutions for the pharmaceutical industry and biotechnology, available in the UK from Labtex

Huber offers a world-renowned range of temperature control systems and associated accessories for the Pharmaceutical Industry and Biotechnology
Manufacturing

WuXi AppTec peptide facility receives PMDA approval

The company's Changzhou oligonucleotide API manufacturing site was approved by Japan's Pharmaceuticals and Medical Devices Agency
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Ardena's nanomedicines facility marks expansion with first GMP approval

The EUR €20m expansion to the nanomedicines facility at Pivot Park has achieved operational status by the Dutch Healthcare Authority
Subscribe now